$ABOS News

Acumen Pharmaceuticals and Unlearn Collaborate to Explore Analyses of Alzheimer's Disease Clinical Programs

Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

Acumen Pharmaceuticals To Present Data On Three Trials At Alzheimer's Association International Conference 2026

JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform

Acumen Pharmaceuticals Exercises Option For Development, Production, Commercialization Of Two Candidates To Treat Alzheimer's Disease Through JCR Pharmaceuticals' Blood-Brain Barrier -Penetrating Technology Platform J-Brain Cargo

Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease

Acumen Pharmaceuticals Nominates Two Development Candidates In Its Enhanced Brain Delivery Program For Alzheimer's Disease Treatments, IND Submission Expected In Mid-2027

Acumen's Late-2026 Sabirnetug Readout Is A Viable Bet

Acumen Pharmaceuticals, Inc. (ABOS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Acumen Pharmaceuticals Inc (ABOS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...

Acumen Pharmaceuticals Q1 Earnings Call Highlights

Acumen Pharmaceuticals (NASDAQ:ABOS) Q1 2026 Loss Narrows as Phase 2 Alzheimer's Trial Readout Looms

Acumen Pharmaceuticals, Inc. (ABOS) Q1 2026 Earnings Call Transcript

Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights

Acumen Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript

Acumen Pharmaceuticals Q1 EPS $(0.33) Beats $(0.36) Estimate

Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference

Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026

Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Acumen Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary